

# Emine Salva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2950072/publications.pdf>

Version: 2024-02-01

28  
papers

324  
citations

933447

10  
h-index

888059

17  
g-index

29  
all docs

29  
docs citations

29  
times ranked

479  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of biological activities of <i>Barbarea integrifolia</i> and isolation of a new glucosinolate derivated compound. <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2021, 76, 375-382.	1.4	2
2	Synthesis and cytotoxicity studies on new pyrazolecontaining oxime ester derivatives. <i>Tropical Journal of Pharmaceutical Research</i> , 2021, 18, 1315-1322.	0.3	3
3	Therapeutic Silencing of BCL-2 Using NK Cell-Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer. <i>Cancers</i> , 2021, 13, 2397.	3.7	39
4	Synthesis of New 1-Aryl-2-(3,5-dimethylpyrazol-1-yl)ethanone Oxime Ether Derivatives and Investigation of Their Cytotoxic Effects. <i>Processes</i> , 2021, 9, 2019.	2.8	2
5	Relationship between guanosine triphosphate pathway and tetrahydrobiopterin in gestational diabetes mellitus. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1391-1396.	1.9	3
6	p-Trifluoroacetophenone Oxime Ester Derivatives: Synthesis, Antimicrobial and Cytotoxic Evaluation and Molecular Modeling Studies. <i>Letters in Drug Design and Discovery</i> , 2020, 17, 169-183.	0.7	3
7	Modulation of the dual-faced effects of miR-141 with chitosan/miR-141 nanoplexes in breast cancer cells. <i>Journal of Gene Medicine</i> , 2019, 21, e3116.	2.8	11
8	The effectiveness of chitosan-mediated silencing of PDGF-B and PDGFR- $\beta$ in the mesangial proliferative glomerulonephritis therapy. <i>Experimental and Molecular Pathology</i> , 2019, 110, 104280.	2.1	13
9	Synthesis of triazolymethyl-linked nucleoside analogs via combination of azidofuranoses with propargylated nucleobases and study on their cytotoxicity. <i>Chemistry of Heterocyclic Compounds</i> , 2018, 54, 158-166.	1.2	7
10	Inhibition of Glomerular Mesangial Cell Proliferation by siPDGF-B- and siPDGFR- $\beta$ -Containing Chitosan Nanoplexes. <i>AAPS PharmSciTech</i> , 2017, 18, 1031-1042.	3.3	9
11	<i>In Vitro</i> Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells. <i>Nucleic Acid Therapeutics</i> , 2017, 27, 45-55.	3.6	26
12	Syntheses of 1,2,3-triazole-bridged pyranose sugars with purine and pyrimidine nucleobases and evaluation of their anticancer potential. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2017, 36, 598-619.	1.1	10
13	The Effects to GM-CSF Expression and Fibroblast Proliferation of pGMCSF Containing Chitosan/PVP Hydrogels. <i>Marmara Pharmaceutical Journal</i> , 2017, 21, 223-223.	0.5	4
14	Non-viral siRNA and shRNA Delivery Systems in Cancer Therapy. , 2016, , .		1
15	152. Tumor Inhibition by Using Chitosan:siRNA PDGFR- $\beta$ in Breast Cancer Model of Rat. <i>Molecular Therapy</i> , 2016, 24, S60.	8.2	0
16	Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model. <i>Molecular and Cellular Biochemistry</i> , 2016, 420, 21-28.	3.1	24
17	The effects of chitosan/miR-200c nanoplexes on different stages of cancers in breast cancer cell lines. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 95, 103-110.	4.0	20
18	Generation of stable cell line by using chitosan as gene delivery system. <i>Cytotechnology</i> , 2016, 68, 1033-1038.	1.6	0

#	ARTICLE	IF	CITATIONS
19	In vitro PDGF-B gene silencing studies and In vivo delivery of siRNA to the rat kidney using Chitosan/siRNA nanoplexes. Marmara Pharmaceutical Journal, 2016, 20, 263.	0.5	2
20	594. PDGF-D Inhibition by Using Chitosan:siRNA Complexes in Breast Cancer Model of Rat. Molecular Therapy, 2015, 23, S236.	8.2	1
21	The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1 $\alpha$ and VEGF. International Journal of Pharmaceutics, 2015, 478, 147-154.	5.2	44
22	Comparison of VEGF gene silencing efficiencies of chitosan and protamine complexes containing shRNA. Cell Biology International, 2014, 38, 1260-1270.	3.0	5
23	Investigation of the Therapeutic Efficacy of Codelivery of siRNA "Vascular Endothelial Growth Factor and pIL-4 into Chitosan Nanoparticles in the Breast Tumor Model. Journal of Pharmaceutical Sciences, 2014, 103, 785-795.	3.3	17
24	The Development of Ternary Nanoplexes for Efficient Small Interfering RNA Delivery. Biological and Pharmaceutical Bulletin, 2013, 36, 1907-1914.	1.4	9
25	Local Delivery of Chitosan/VEGF siRNA Nanoplexes Reduces Angiogenesis and Growth of Breast Cancer <i>In Vivo</i> . Nucleic Acid Therapeutics, 2012, 22, 40-48.	3.6	38
26	Halofuginone, a Specific Inhibitor of Collagen Type I Synthesis, Ameliorates Oxidant Colonic Damage in Rats with Experimental Colitis. Digestive Diseases and Sciences, 2010, 55, 607-616.	2.3	9
27	Chitosan/Short Hairpin RNA Complexes for Vascular Endothelial Growth Factor Suppression Invasive Breast Carcinoma. Oligonucleotides, 2010, 20, 183-190.	2.7	20
28	Investigation of therapeutic effects in the wound healing of chitosan/pGM-CSF complexes. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	2